Anti-CB1 cannabinoid receptor antibody - Materia Medica
Alternative Names: DietressaLatest Information Update: 05 Aug 2015
At a glance
- Originator Materia Medica Holding Research and Production Company
- Class Antibodies; Obesity therapies
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 05 Aug 2015 No recent reports on development identified - Phase-III for Obesity in Russia (PO)
- 01 Jun 2013 Materia Medica completes a phase III trial in Obesity in Russia (NCT01570829)
- 01 Jun 2013 Materia Medica completes a phase III trial in Obesity in Russia (NCT01535014)